Skylabs announced that it has signed a new contract with Daewoong Pharmaceutical for the sale of CART O2 (ring-type pulse oximeter, SpO2) worth 4.9 billion won. According to the regulatory filing, the confirmed contract amount is 4.9 billion won, equivalent to 61.74% of the company's most recent revenue of 7.93586 billion won based on 2025 separate financial statements. The contract amount excludes value-added tax (VAT). The counterparty is Daewoong Pharmaceutical, and the sales and supply region is South Korea. The contract period runs from September 30, 2026 to November 30, 2026, with the contract signed on September 30, 2026. There is no down payment or advance payment, and payment is due within 30 days of the invoice date. The sales and supply method covers both in-house and outsourced production. Skylabs stated in its filing that it is 'not applicable' regarding whether it has performed similar contracts with Daewoong Pharmaceutical over the past three years. Meanwhile, Skylabs was listed on the KOSDAQ market on the 4th of last month. [※ This article is for investment reference purposes only and does not constitute a recommendation to invest in any specific stock. All investments are made at the investor's own discretion, and the final responsibility for buying and selling rests with the investor.]